Jane Street’s Adamas Pharmaceuticals ADMS Stock Holding History

Jane Street’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-22,226	Closed	-$92K	–	8411
2020 Q3	$92K	Sell	22,226 -115,066	-84%	-$445K	﹤0.01%	6775
2020 Q2	$351K	Buy	+137,292	New	+$403K	﹤0.01%	5608
2020 Q1	–	Sell	-20,918	Closed	-$79K	–	6259
2019 Q4	$79K	Sell	20,918 -18,026	-46%	-$86.3K	﹤0.01%	4870
2019 Q3	$199K	Buy	+38,944	New	+$240K	﹤0.01%	4654
2019 Q1	–	Sell	-42,714	Closed	-$365K	–	5900
2018 Q4	$365K	Buy	42,714 +26,527	+164%	+$345K	﹤0.01%	3841
2018 Q3	$324K	Buy	+16,187	New	+$380K	﹤0.01%	4121
2017 Q4	–	Sell	-12,339	Closed	-$261K	–	5373
2017 Q3	$261K	Sell	12,339 -1,210	-9%	-$22.2K	﹤0.01%	3850
2017 Q2	$237K	Buy	+13,549	New	+$224K	﹤0.01%	3861
2016 Q2	–	Sell	-12,186	Closed	-$176K	–	4776
2016 Q1	$176K	Buy	+12,186	New	+$205K	﹤0.01%	3758
2014 Q3	–	Sell	-29,826	Closed	-$545K	–	3232
2014 Q2	$545K	Buy	+29,826	New	+$534K	0.01%	1339

Other funds holding ADMS

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Jane Street's ADMS Position: Q4 2020 in Review

Jane Street sold out of Adamas Pharmaceuticals (ADMS) in Q4 2020, closing a stake of 22,226 shares — an estimated $92K sold.

Jane Street first reported a position in ADMS in Q2 2014 and held it in 10 quarters. The position peaked at $545K in Q2 2014. 65 funds tracked by Wall St. Rank hold ADMS as of Q4 2020.

Jane Street reported no remaining Adamas Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Jane Street sold 22,226 Adamas Pharmaceuticals shares in Q4 2020, an estimated $92K.
Jane Street first reported a position in Adamas Pharmaceuticals in Q2 2014 and held it in 10 quarters.
Jane Street's Adamas Pharmaceuticals position peaked at $545K in Q2 2014.
65 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2020.

Based on Jane Street's 13F filing for Q4 2020, filed 17 Feb 2021.